Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Strategies for the treatment and management of PIDs

From: Primary immunodeficiency

  Supportive Definitive
CIDs/SCID Ig replacement therapy (IV or SC)
Antibiotic prophylaxis
Antifungal prophylaxis
Aggressive management of established infections
Infectious precautions when hospitalized
Withhold all live vaccines
BMT
HSCT
Gene therapy a possibility for some SCIDs
B-cell disorders Ig replacement therapy (IV or SC)
Antibiotic prophylaxis
Antifungal prophylaxis depending upon etiology
Hearing assessment
Assessment of pulmonary status and function
Close monitoring for co-morbidities
Gene therapy is a potential future treatment in some patients
Innate disorders Antibiotic prophylaxis
Antifungal prophylaxis
Cytokine replacement (IFNγ) for CGD
Vaccinations (e.g., meningococcal)
Ig replacement is sometimes indicated
BMT, e.g., for CGD
Gene therapy is a potential future treatment
  1. Ig immunoglobulin, IV intravenous, SC subcutaneous, CID combined immunodeficiency, SCID severe combined immunodeficiency, IFNγ interferon-γ, BMT bone marrow transplantation, CGD chronic granulomatous disease, HSCT hematopoietic stem cell transplantation